#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

Summary of #384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

by Peter Attia, MD

52m•March 16, 2026
Listen to Episode

Overview of #384 — Special episode: Obicetrapib — The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

Host: Peter Attia, MD (The Drive)

This episode is a deep-dive on obicetrapib, a CETP (cholesteryl ester transfer protein) inhibitor that has re‑sparked interest in the CETP class. Attia reviews CETP biology and the checkered history of CETP inhibitors, summarizes the Phase 2/3 lipid data that distinguish obicetrapib from earlier drugs, and walks through a pre‑specified biomarker sub‑study (the Broadway biomarker study) with provocative Alzheimer’s‑related blood biomarker effects — most notably in APOE4 homozygotes. He explains biologic plausibility for why a plasma lipoprotein drug could influence brain lipid biology, outlines limitations, and recommends the next studies needed to determine clinical efficacy for cognitive outcomes.

Key takeaways

  • Obicetrapib is a CETP inhibitor that robustly lowers LDL‑C and apoB while markedly raising HDL‑C and reducing Lp(a). Unlike several earlier CETP drugs, its lipid effects appear large and clinically meaningful.
  • Broadway (a phase 3 lipid trial with a pre‑specified biomarker sub‑study) found attenuation of plasma p‑tau‑217 progression over 12 months with obicetrapib vs placebo — strongest and most striking in APOE4/4 carriers (n=29).
  • The biomarker signal is biologically plausible (APOA1/HDL biology, small HDL crossing into CNS, antioxidant delivery, improved lipid handling) but remains preliminary: this was a 12‑month biomarker study, not a cognitive outcomes trial.
  • Europe may approve obicetrapib on biomarker/lipid grounds (anticipated Q4 2026); the U.S. will likely wait for clinical outcome data (PREVAIL cardiovascular outcome trial and potentially cognitive trials).
  • A dedicated, prospective prevention trial enriched for APOE4 carriers with cognitive endpoints, imaging, and long follow‑up is warranted.

CETP biology — concise primer

  • Lipoproteins shuttle cholesterol in blood; ApoB‑containing particles (VLDL→IDL→LDL) are atherogenic, ApoA1‑containing particles (HDL) mediate reverse cholesterol transport (RCT).
  • Indirect RCT: HDL (cholesterol esters) exchanges with triglyceride in ApoB particles; CETP mediates that exchange. High CETP activity → cholesterol moves into LDL (LDL becomes cholesterol‑rich; HDL becomes triglyceride‑rich and unstable).
  • CETP inhibition → less cholesterol ester leaves HDL → larger, cholesterol‑rich HDL (HDL‑C up) and lower LDL‑C/ApoB (desired cardiovascular effect).
  • Some small, lipid‑poor HDL/ApoA1 particles can cross the blood‑brain barrier (to a limited extent), potentially affecting CNS lipid handling.

History of CETP inhibitors (why earlier failures matter)

  • Torcetrapib (Pfizer): raised HDL massively but increased mortality via off‑target blood pressure effects → trial stopped (2006).
  • Dalcetrapib (Roche): raised HDL but did not meaningfully lower LDL/ApoB → no outcome benefit → abandoned (2012).
  • Evacetrapib (Eli Lilly): large HDL rise, modest LDL/ApoB reductions; effect too small/too short to show CV benefit → program stopped (2015).
  • Anacetrapib (Merck, REVEAL trial): modest but consistent CV event reduction (~9–12% over 4–6 years), concordant with measured apoB lowering; drug had long half‑life and tissue retention → development stopped.
  • Lesson: raising HDL alone is not sufficient; clinically meaningful apoB/LDL lowering (and acceptable safety) are critical.

Obicetrapib — lipid trial results and programs

  • Phase 2 highlights:
    • ROSE: added to high‑intensity statin therapy → additional ~50% LDL‑C reduction; apoB ~30% reduction.
    • OCEAN: combined with ezetimibe (10 mg) → ~52% LDL‑C reduction.
    • ROSE2: statin + ezetimibe + obicetrapib → >60% LDL‑C reduction.
  • Phase 3 programs: Broadway (lipid patients on max therapy with biomarker sub‑study), Brooklyn (familial hypercholesterolemia on max therapy), PREVAIL (cardiovascular outcomes in patients with established disease).
  • Broadway (lipid endpoints): in patients on maximal lipid therapy, 10 mg obicetrapib -> LDL‑C fell ~30% at 3 months vs +3% in placebo; apoB −16% vs +1.8% placebo. HDL‑C rose (≈125%) and Lp(a) fell ≈33%.

Broadway biomarker sub‑study — Alzheimer’s biomarkers (concise results)

Design:

  • Pre‑specified cardiovascular trial sub‑study measuring plasma Alzheimer’s biomarkers over 12 months.
  • Primary biomarker: plasma P‑tau‑217. Secondary: P‑tau‑181, Aβ42/40 ratio, GFAP, neurofilament light (NfL), P‑tau/Aβ ratio.
  • Participants: ~1,500 with median age 67, no dementia, had cardiovascular disease; stratified by APOE genotype (3/3, 3/4, 4/4).

Main findings:

  • Overall: placebo P‑tau‑217 rose ~5% over 12 months vs ~2% in obicetrapib group (attenuation statistically significant).
  • APOE4 carriers (3/4 + 4/4): placebo +7% vs obicetrapib +1.5%.
  • Age >70 APOE4 subgroup: placebo P‑tau‑217 rose ≈15% vs obicetrapib ≈6%.
  • APOE4/4 (n=29): placebo +12.7% P‑tau‑217 vs obicetrapib −7.7% → ~20% difference (statistically significant despite small n).
  • Other biomarker differences in APOE4/4 (treatment vs placebo): NfL ~17% difference, GFAP ~15%, P‑tau‑181 ~14%, Aβ42/40 ~8%, P‑tau/Aβ ratio ~23% — all trending in favorable directions.
  • No biomarker moved in an unexpected or adverse direction.

Plausible mechanisms linking CETP inhibition to brain biology

  • Increased circulating ApoA1/HDL may raise the pool of small, functional HDL/ApoA1 that can cross into CNS (limitedly) and augment cholesterol efflux where APOE‑mediated transport is defective (especially in APOE4).
  • Improved peripheral lipid handling (lower apoB, lower Lp(a)) reduces cerebrovascular risk (less vascular injury/ischemia that can accelerate neurodegeneration).
  • HDL carries lipophilic antioxidants and anti‑inflammatory cargo; raising functional HDL could reduce oxidative stress/lipid peroxidation and neuroinflammation.
  • In APOE4 carriers (less efficient brain lipid trafficking), increasing alternate lipid transport (via ApoA1/HDL) may most benefit neuronal lipid homeostasis — consistent with largest biomarker effects in APOE4/4.

Limitations and cautions

  • This was a biomarker study (primary endpoint plasma p‑tau‑217) over 12 months — not a cognitive outcomes or dementia prevention trial. Biomarker improvement does not prove clinical benefit.
  • Short duration relative to Alzheimer’s natural history (decades). Unknown if effects persist or translate to reduced incidence/ slower clinical decline.
  • APOE4/4 subgroup was small (n=29) — impressive signal but requires replication in larger, dedicated cohorts.
  • Mechanisms remain plausible but not proven; exact causal pathway (which lipid change causes which CNS effect) is not established.
  • Regulatory/approval differences: Europe may approve sooner on biomarker/lipid grounds; U.S. likely requires CV outcomes (and would likely want cognition data before any claim about Alzheimer’s prevention).

Practical implications (for clinicians, researchers, and patients)

For clinicians:

  • Obicetrapib looks promising for lipid management (robust LDL‑C and apoB reduction, Lp(a) lowering, possible metabolic neutrality or benefit). Watch PREVAIL outcomes and regulatory news.
  • Do not change practice yet for Alzheimer’s prevention — no cognitive outcome data. Discuss cautiously with patients who ask; emphasize biomarker nature of the evidence.

For researchers / trial designers:

  • A definitive prevention trial should be prospective, enriched for APOE4 (large numbers of 3/4 and many 4/4), enroll cognitively intact mid‑life/older adults, include:
    • Sensitive longitudinal cognitive endpoints,
    • Serial plasma biomarkers (p‑tau‑217, Aβ42/40, NfL, GFAP),
    • Imaging (amyloid/tau PET, structural MRI) where feasible,
    • Long follow‑up (multiple years),
    • Adequate sample size to power APOE‑stratified analyses.

For patients / public:

  • The data are encouraging but preliminary. Obicetrapib is not yet proven to prevent or slow clinical Alzheimer’s; talk with clinicians about cardiovascular indications once/if approved.

Notable concise quotes from the episode

  • “I haven't been as excited about any drug in the market or a drug that's about to enter the market as I am with respect to this drug.” — Attia’s personal assessment of obicetrapib.
  • “This is a biomarker study that was internally coherent and very genotype specific. I think it has very high biologic plausibility — but biomarkers don't establish clinical benefit.”

Next steps and what to watch

  • PREVAIL (cardiovascular outcome trial) results — will inform clinical cardiovascular benefit and U.S. regulatory timing.
  • Larger and longer Alzheimer’s‑focused trials (prospective, APOE‑enriched, with cognitive outcomes and imaging) to test whether biomarker changes translate into clinical prevention.
  • European regulatory/launch updates (anticipated Q4 2026 timeline mentioned).
  • Replication of Broadway biomarker findings in independent cohorts or longer follow‑ups.

For deeper reading: Attia referenced the Broadway biomarker substudy (p‑tau‑217 primary endpoint) and the ROSE/OCEAN/ROSE2 phase 2 data; those primary sources are recommended for anyone who wants detailed numbers and methods.